A Surgical Method to Improve the Homeostasis of CSF for the Treatment of Alzheimer’s Disease by Yang Qin & Jian W. Gu
HYPOTHESIS AND THEORY
published: 02 November 2016
doi: 10.3389/fnagi.2016.00261
A Surgical Method to Improve the
Homeostasis of CSF for the
Treatment of Alzheimer’s Disease
Yang Qin 1 and Jian W. Gu 1,2*
1 Department of Neurosurgery, Chengdu Military General Hospital, Chengdu, China, 2 Department of Neurosurgery,
The 306th Hospital of PLA, Beijing, China
Edited by:
Aurel Popa-Wagner,
University of Rostock, Germany
Reviewed by:
Ramesh Kandimalla,
Texas Tech University, USA
Magda Tsolaki,





Received: 12 May 2016
Accepted: 19 October 2016
Published: 02 November 2016
Citation:
Qin Y and Gu JW (2016) A Surgical
Method to Improve the Homeostasis
of CSF for the Treatment of
Alzheimer’s Disease.
Front. Aging Neurosci. 8:261.
doi: 10.3389/fnagi.2016.00261
Reduced cerebrospinal fluid (CSF) production and increased resistance to CSF outflow
are considered to be associated with aging, and are also characteristics of Alzheimer’s
disease (AD). These changes probably result in a decrease in the efficiency of the
mechanism by which CSF removes toxic molecules such as amyloid-β (Aβ) and tau
from the interstitial fluid space. Soluble Aβ is potently neurotoxic and dysfunctional in
CSF circulation and can accelerate the progression of AD. Current therapies for AD
exhibit poor efficiency; therefore, a surgical method to improve the homeostasis of
CSF is worthy of investigation. To achieve this, we conceived a novel device, which
consists of a ventriculo-peritoneal shunt, an injection port and a portable infusion
pump. Artificial CSF (ACSF) is pumped into the ventricles and the ACSF composition,
infusion modes and pressure threshold of shunting can be adjusted according to the
intracranial pressure and CSF contents. We hypothesize that this active treatment for
CSF circulation dysfunction will significantly retard the progression of AD.
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INTRODUCTION
Alzheimer’s disease (AD) is an age-related dementia that represents a serious social problem
in the aging population worldwide (Kandimalla et al., 2011, 2014; Marešová et al., 2015). This
chronic degenerative disease of the brain is characterized clinically by progressive deterioration
of memory and other cognitive domains, along with profound changes in personality and
behavior (Dubois et al., 2015). Amyloid-β (Aβ) and protein tau have long been recognized
as the major pathogenic factors (Kandimalla et al., 2013), and are highlighted in the major
consensus criteria for the diagnosis of AD at autopsy (Mirra et al., 1991). The exact etiology of
AD is unclear, but it is presumed to include factors such as age, genetics, inflammation, head
trauma, etc. (Castellani et al., 2010). Currently, cholinesterase inhibitors and memantine are
the only treatments that were widely confirmed to be marginally beneficial for AD patients
(Schmidt et al., 2015). Although not yet fully confirmed, other protocols that are expected to be
beneficial include: increasing the cerebral blood flow, which is believed to be able to delay and
even improve the clinical presentation of AD (Goldsmith, 2014); nerve growth factor, which
can prevent neuronal degeneration (Tuszynski, 2007); antioxidants (Zandi et al., 2004); statins,
which may decrease cerebral Aβ (Barone et al., 2014); non-steroidal anti-inflammatory drugs,
which may lower Aβ production (McGeer and McGeer, 2013); hormone replacement therapy, in
which estrogen enhances cerebral blood flow, preventing cholinergic neuron atrophy, reducing
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oxidative stress, and modulating the effects of nerve growth
factors (Goutte et al., 2002); blocking of excitotoxicity, which
has been approved for treating the advanced stages of AD
(Kurz and Grimmer, 2014); a Mediterranean diet (Singh et al.,
2014); the Aβ vaccine, which removes excess Aβ from the brain
by activating specific T cell responses (Gilman et al., 2005);
immunotherapy, which is used to reduce the Aβ load in the
brain (Paquet et al., 2015) and induce the secretion of effectors,
which inhibit the protease that initiates cleavage of Aβ protein
precursor leading to the production of Aβ (Chang et al., 2007);
and neural stem cells transplantation, which may be capable of
replacing lost or damaged cells and reverse the course of AD
(Zhang et al., 2013). Most of these treatments were evaluated
in Aβ-based therapeutic trials, which indicated that Aβ is a
breakthrough point in the development of cure for AD. However,
so far, the results have not met with these high expectations
(Iqbal et al., 2014). As the therapeutic based on decreasing
amyloid plaque remains suboptimal and phosphorylated tau
plays an important role in the pathological process of AD,
the therapy was moving from Aβ to tau (Giacobini and Gold,
2013).
The physiological functions of cerebrospinal fluid (CSF),
which is the internal environment of the brain, include
amortization, acid-base buffering and transport of electrolytes,
molecules and micronutrients (Spector et al., 2015). Normal
CSF circulation is important to ensure homeostasis of the
internal environment of the brain. Unfortunately, with aging,
CSF production decreases and outflow resistance increases (May
et al., 1990). In the elderly, the CSF synthesized by choroid
plexus may decrease as much as 50% (Serot et al., 2003). These
changes may disrupt CSF homeostasis and delay clearance of
toxic molecules such as Aβ from the interstitial fluid space.
Although diffuse amyloid plaques that are typically composed of
Aβ are pathognomonic for AD, they are unlikely to be potently
neurotoxic (Chaudhury et al., 2003). Conversely, soluble Aβ is
highly neurotoxic, with effects ranging from the induction of
cell death to disruption of normal neuronal function (Nichols
et al., 2015). A recent study suggested that, during the very
early stages of AD, Aβ in CSF may significantly increase (Maia
et al., 2015). With the progression of AD, CSF Aβ has decreased
and pronounced Aβ has deposited in the choroid plexus and
arachnoid granulations, where the CSF is produced and absorbed
(Kalaria et al., 1996). Aβ deposition exacerbates the dysfunction
in CSF circulation in a vicious cycle that eventually triggers,
or at least contributes to, the development of AD (Rubenstein,
1998).
To our knowledge, no animal experiments have confirmed
that it is beneficial to AD by directly promoting the circulation
of CSF. However, caffeine, which can increase production of
CSF, was proven to be beneficial for Alzheimer animals and
patients (Han et al., 2009; Cao et al., 2011; Kromhout et al.,
2014). In a clinical study evaluating the effect of low-flow
CSF drainage in the treatment of AD, a trend in favor of the
treated group was observed, although the effect did not reach
the level of statistical significance (Silverberg et al., 2002). We
speculate that the reason why no better results were obtained
may be due to the fact that CSF drainage improved the outflow
resistance but did not effectively reinstate homeostasis of the
CSF. According to the current hypothesis, a more aggressive
therapy was conceived to recover the homeostasis and retard the
progression of AD.
MATERIALS AND METHODS
A novel device was designed to improve CSF circulation.
The device consists of three main parts: an adjustable
pressure ventriculo-peritoneal shunt, an injection port
and portable infusion pump. The shunt and the port are
connected and form a double-lumen tube to enter the
ventricles of the brain. The pump, which is connected
to the injection port by an infusion apparatus with an L
type non-coring needle, can accommodate 150 ml artificial
CSF (ACSF) and accurately control the infusion process
(Figure 1).
The required implantation of the ventriculo-peritoneal shunt
and the injection port is performed under general anesthesia
using a surgical procedure similar to that used for shunt
implantation described previously (Silverberg et al., 2002). The
proximal and the distal ends of the catheter are placed into the
frontal horn of the lateral ventricle and the peritoneal cavity,
FIGURE 1 | Structure diagram of the cerebrospinal fluid (CSF)
circulatory assistance device. 1. CSF outlet; 2. Artificial CSF (ACSF) inlet;
3. Intraventricular double lumen catheter; 4. A one-way liquid storage bag;
5. Subcutaneous double lumen catheter; 6. Transfusion connecting tube;
7. Pressure control valve; 8. Peritoneal cavity catheter; 9. Infusion seat;
10. L-shaped nondestructive needle; 11. Needle connecting head; 12. Fluid
needle; 13. Pre-packaged ACFS; 14. Infusion pump.
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FIGURE 2 | Schematic diagram of the CSF circulatory assistance
device.
respectively. The infusion port is implanted under the skin of the
chest. The portable infusion pump can be carried by the patient
(Figure 2).
The main operation mode of the device allows injection
of the ACSF into the lateral ventricles to supplement the
insufficient CSF, as well as drainage of the supernumerary
CSF through the shunt tube. An infusion bottle containing
150 ml ACSF, which is approximately equivalent to the total
amount of CSF in normal adults, is placed in the infusion
pump. The ACSF is pumped continuously and slowly into
the ventricles over a period of 8–12 h during the daytime.
The amount of the ACSF is adjusted by measuring biological
markers in the CSF such as Aβ and tau, with the aim of
restoring the composition of the CSF. The difference between
the intracranial pressure and the valve pressure is set at
0–20 cm H2O to minimize the drainage rate and maximize the
CSF turnover efficiency. For patients accompanied by normal
pressure hydrocephalus (NPH), the difference can be adjusted to
20–40 cm H2O.
DISCUSSION
The hypothesis that dysfunctional CSF circulation is involved
in the pathogenesis of AD presents a novel therapeutic target
for this disorder. Here, we describe a device that was designed
for the treatment of AD according to this hypothesis. The
therapy promotes CSF circulation by direct intervention in all
stages of the circulation: production, turnover and clearance.
CSF production in patients with AD insignificantly decreased
to approximately 300 ml per day; about half the amount of
normal people (Silverberg et al., 2001). In a normal adult with
a total CSF volume of 150 ml, the CSF turnover rate is about
four times per day. In patients with AD, reduced CSF production
and enlarged ventricles cause a reduction in the turnover rate to
less than 1.5 times per day. Normally, the clearance of Aβ and
other neurotoxic macromolecules from the CSF is quite rapid
(Ghersi-Egea et al., 1996). This process requires the continuous
formation of fresh CSF to drain the macromolecular solutes
in the interstitial fluid from the Virchow Robin space down
concentration gradients into the subarachnoid space and from
there, into the bloodstream (Nakada, 2015). The clearance is
severely reduced in AD patients due to the dysfunction in CSF
production and turnover, as well as the disappearance of the
capillary receptors that transport Aβ from the CSF into blood
(Mackic et al., 1998). Although the present treatment cannot
restore normal physiological CSF circulation directly, especially
not improve the production of intercellular fluid, which is driven
by aquaporin-4 and very important for the clearance of Aβ
and other toxins (Nakada, 2014); it can play a similar role in
other form to improve CSF circulation. Briefly, the insufficient
CSF production can be compensated by direct injection. By
adjusting the injection speed and shunt pressure difference, the
drainage volume and speed can be controlled to allow sufficient
time and space for the turnover between CSF and ACSF. The
result is the increase of the solute concentration difference
between the CSF and the interstitial fluid, which may facilitate
the free diffusion and dilution of neurotoxic substances so as
to achieve the purpose of clearance. In the drainage phase, the
Aβ that is not cleared by the receptor can also be discharged
through the drainage tube. It needs to be pointed out that
the manuscript has no intention to emphasize Aβ and ignore
other potential factors. What we have done is to take Aβ as
an example to illustrate the importance of CSF homeostasis
for AD.
Previous studies have shown numerous similarities between
AD and idiopathic NPH, including age of onset, clinical
symptoms and Aβ accumulation (Graff-Radford, 2014; Martín-
Láez et al., 2015). Clinical benefits have been demonstrated in
a clinical trial using a form of ventriculo-peritoneal shunting,
which is usually used in the treatment of NPH, for the treatment
of AD, although the effects were not statistically significant
(Silverberg et al., 2002). Hence we designed a more aggressive
treatment plan for AD. However, not all the AD patients may
benefit from this treatment. The goal of the therapeutic strategy is
to delay the progression of AD rather than to cure it. The present
treatment may not be suitable for the dementia stage patients
whose large number of neurons have died or deteriorated. We
hypothesized that it is suitable for the patients at the stage of
mild cognitive impairment or preclinical stage, when the CSF
composition has changed. Of course, the patient’s tolerogenic
capability to anesthesia and surgery must also be considered
important. The adverse events associated with the treatment may
be similar to those reported for ventriculo-peritoneal shunting,
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especially catheter infection or obstruction; and it remains to be
established in clinical trials.
The treatment hypothesis is based on the existing theory and
limited indirect animal experiments and clinical trials. It is still
at most preliminary. First of all, it needs to be supported by the
results of direct animal experiment, which has not been clearly
designed so far. Furthermore, a fully developed device that can be
used in clinical trials is also not yet available. Although there is no
technical barrier to the production of the equipment in its current
form, financial investment is urgently needed to complete the
work.We expect the preliminary idea would provide a novel view
of the treatment of AD.
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